Sanofi (ETR:SNW)

Germany flag Germany · Delayed Price · Currency is EUR
81.70
+1.71 (2.14%)
Aug 4, 2025, 5:35 PM CET
2.14%
Market Cap100.00B
Revenue (ttm)45.74B
Net Income (ttm)9.13B
Shares Outn/a
EPS (ttm)7.36
PE Ratio10.96
Forward PE10.05
Dividend3.92 (4.80%)
Ex-Dividend DateMay 12, 2025
Volume10,708
Average Volume10,488
Open80.32
Previous Close79.99
Day's Range80.10 - 81.70
52-Week Range77.85 - 110.82
Beta0.40
RSI35.67
Earnings DateJul 31, 2025

About Stronghold Digital Mining

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; inf... [Read more]

Sector Healthcare
Founded 1994
Employees 82,878
Stock Exchange Deutsche Börse Xetra
Ticker Symbol SNW
Full Company Profile

Financial Performance

In 2024, Sanofi's revenue was 44.29 billion, an increase of 7.73% compared to the previous year's 41.11 billion. Earnings were 5.56 billion, an increase of 2.96%.

Financial Statements

News

Pharmaceutical makers were largely unshaken by new demands from President Trump to lower drug prices, with experts saying the measures would either have modes impact or face legal challenges

Measures laid out in letters to 17 companies would either have modest impact or face legal challenges, say industry experts.

3 days ago - WSJ

European drugmakers fall after Trump raises stakes over US drug price cuts

Shares of European drugmakers slipped on Friday after U.S. President Donald Trump sent letters to major pharmaceutical firms to cut drug prices in the United States, months after signing a sweeping ex...

3 days ago - Reuters

Sanofi (SNY) Q2 2025 Earnings Call Transcript

Sanofi (NASDAQ:SNY) Q2 2025 Earnings Conference Call July 31, 2025 8:30 AM ETCompany ParticipantsBrian Foard - Executive VP & Head of Specialty...

4 days ago - Seeking Alpha

Pharma Companies Should Immediately Cut Down Drug Prices, Trump Says

President Donald Trump demanded several pharmaceutical companies cut down their drug prices for American consumers Thursday, issuing a Sept. 29 deadline for the businesses to “end the free ride of Ame...

4 days ago - Forbes

Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days.

President Donald Trump on Thursday said he asked major pharmaceutical companies to take steps to cut U.S. drug prices within the next 60 days.

4 days ago - CNBC Television

Trump pressures 17 pharma CEOs to cut US drug prices

U.S. President Donald Trump sent letters to the chief executives of 17 major pharmaceutical companies, urging immediate action to lower the cost of prescription drugs for Americans, the White House sa...

4 days ago - Reuters

Trump posts letters to 17 pharmaceutical companies about drug prices

CNBC's Angelica Peebles joins 'The Exchange' to discuss President Trump posting letters to 17 pharmaceutical companies about drug prices.

4 days ago - CNBC Television

Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days

President Donald Trump said he asked major pharmaceutical companies to take steps to cut U.S. drug prices within the next 60 days. It comes after Trump in May signed an executive order reviving a cont...

4 days ago - CNBC

Press release: Online availability of Sanofi's half-year financial report for 2025

Online availability of Sanofi's half-year financial report for 2025 Paris, July 31, 2025. Sanofi announces that its half-year financial report for the period ending June 30, 2025 is now available and ...

4 days ago - GlobeNewsWire

Press release: Online availability of Sanofi's half-year financial report for 2025

Online availability of Sanofi's half-year financial report for 2025 Paris, July 31, 2025 . Sanofi announces that its half-year financial report for the period ending June 30, 2025 is now available and...

4 days ago - Benzinga

Sanofi's Q2 Earnings Fall Short On Expectations Despite 21% Jump In Dupixent Sales

Sanofi SA  SNY reported second-quarter sales of $11.33 billion (€9.99 billion euros), narrowly missing the consensus of $11.53 billion.

4 days ago - Benzinga

Sanofi's Q2 Earnings Fall Short On Expectations Despite 21% Jump In Dupixent Sales

Sanofi SA (NASDAQ: SNY) reported second-quarter sales of $11.33 billion (€9.99 billion euros), narrowly missing the consensus of $11.53 billion . Sales increased 6% year over year, up 10.1% in consta...

4 days ago - Benzinga

Sanofi CEO Paul Hudson on Q2 results, Dupixent demand and tariff impact

Sanofi CEO Paul Hudson joins 'Squawk Box' to discuss the company's quarterly earnings results, Blueprint acquisition, strong demand for Dupixent, drug pipeline outlook, impact of tariffs, and more.

4 days ago - CNBC Television

Sanofi CEO Paul Hudson on Q2 results, Dupixent demand and tariff impact

Sanofi CEO Paul Hudson joins 'Squawk Box' to discuss the company's quarterly earnings results, Blueprint acquisition, strong demand for Dupixent, drug pipeline outlook, impact of tariffs, and more.

4 days ago - CNBC

Sanofi revises annual sales growth expectations on strong Dupixent demand

France's Sanofi said on Thursday that it expects annual sales to grow by high single-digit percentage, helped by strong demand for its anti-inflammatory drug Dupixent, as well as vaccines and newer tr...

4 days ago - Reuters

Sanofi gives Q2 results

4 days ago - Seeking Alpha

Press Release: Q2: double-digit sales and solid business EPS growth. 2025 sales guidance is now high single-digit growth, at upper end of range

Q2: double-digit sales and solid business EPS growth. 2025 sales guidance is now high single-digit growth, at upper end of range.

4 days ago - GlobeNewsWire

Press Release: Sanofi's SAR446523, a GPRC5D monoclonal antibody, earns orphan drug designation in the US for multiple myeloma

Sanofi's SAR446523, a GPRC5D monoclonal antibody, earns orphan drug designation in the US for multiple myeloma Designation granted for IgG1-based GPRC5D monoclonal antibody for the potential treatment...

5 days ago - GlobeNewsWire

U.S. and European Union trade deal could cost the pharma industry up to $19 billion

The European Union's trade deal with the United States could cost the pharmaceutical industry between $13 billion and $19 billion as branded medicines become subject to a tariff of 15%, analysts said ...

6 days ago - Fast Company

EU-US trade deal could add up to $19 billion in pharma industry costs, analysts say

The European Union's trade deal with the United States could cost the pharmaceutical industry between $13 billion and $19 billion as branded medicines become subject to a tariff of 15%, analysts said ...

7 days ago - Reuters

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY

NEW YORK , July 27, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sanofi ("Sanofi" or the "Company") (NASDAQ: SNY).  Such investors are advised to contact Daniel...

8 days ago - PRNewsWire

Sanofi (SNY) to Acquire Vicebio in Strategic Expansion

Sanofi (SNY) to Acquire Vicebio in Strategic Expansion

9 days ago - GuruFocus